| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
9,424 |
8,015 |
$286K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
4,591 |
3,682 |
$158K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
3,910 |
2,966 |
$81K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
385 |
289 |
$20K |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
384 |
357 |
$19K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
80 |
58 |
$3K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
58 |
38 |
$2K |
| 76942 |
|
19 |
13 |
$2K |
| 64483 |
|
13 |
12 |
$1K |
| 20611 |
|
17 |
14 |
$811.21 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
688 |
529 |
$165.06 |
| J1030 |
Injection, methylprednisolone acetate, 40 mg |
53 |
43 |
$91.62 |
| G8427 |
Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications |
5,416 |
4,933 |
$0.00 |
| G8509 |
Pain assessment documented as positive using a standardized tool, follow-up plan not documented, reason not given |
1,341 |
1,167 |
$0.00 |
| G8541 |
Functional outcome assessment using a standardized tool not documented, reason not given |
2,683 |
2,455 |
$0.00 |
| G8752 |
Most recent systolic blood pressure < 140 mmhg |
249 |
231 |
$0.00 |
| 4004F |
|
342 |
321 |
$0.00 |
| G8417 |
Bmi is documented above normal parameters and a follow-up plan is documented |
861 |
798 |
$0.00 |
| 3078F |
|
185 |
179 |
$0.00 |
| G8484 |
Influenza immunization was not administered, reason not given |
1,584 |
1,446 |
$0.00 |
| 4040F |
|
191 |
182 |
$0.00 |
| G9899 |
Screening, diagnostic, film, digital or digital breast tomosynthesis (3d) mammography results documented and reviewed |
447 |
417 |
$0.00 |
| 1090F |
|
102 |
96 |
$0.00 |
| G9900 |
Screening, diagnostic, film, digital or digital breast tomosynthesis (3d) mammography results were not documented and reviewed, reason not otherwise specified |
60 |
51 |
$0.00 |
| G8399 |
Patient with documented results of a central dual-energy x-ray absorptiometry (dxa) ever being performed |
17 |
13 |
$0.00 |
| G8400 |
Patient with central dual-energy x-ray absorptiometry (dxa) results not documented, reason not given |
12 |
12 |
$0.00 |
| 1036F |
|
1,824 |
1,631 |
$0.00 |
| 3017F |
|
3,465 |
3,172 |
$0.00 |
| G8756 |
No documentation of blood pressure measurement, reason not given |
859 |
808 |
$0.00 |
| G9903 |
Patient screened for tobacco use and identified as a tobacco non-user |
1,544 |
1,379 |
$0.00 |
| G8432 |
Depression screening not documented, reason not given |
3,638 |
3,316 |
$0.00 |
| G9717 |
Documentation stating the patient has had a diagnosis of bipolar disorder |
523 |
481 |
$0.00 |
| G8419 |
Bmi documented outside normal parameters, no follow-up plan documented, no reason given |
513 |
458 |
$0.00 |
| G8754 |
Most recent diastolic blood pressure < 90 mmhg |
421 |
395 |
$0.00 |
| G9902 |
Patient screened for tobacco use and identified as a tobacco user |
271 |
254 |
$0.00 |
| G8536 |
No documentation of an elder maltreatment screen, reason not given |
52 |
49 |
$0.00 |
| 3074F |
|
93 |
90 |
$0.00 |
| 1123F |
|
191 |
182 |
$0.00 |
| 1101F |
|
113 |
106 |
$0.00 |
| G9906 |
Patient identified as a tobacco user received tobacco cessation intervention during the measurement period or in the six months prior to the measurement period (counseling and/or pharmacotherapy) |
84 |
81 |
$0.00 |
| 3075F |
|
33 |
32 |
$0.00 |
| G8420 |
Bmi is documented within normal parameters and no follow-up plan is required |
12 |
12 |
$0.00 |